Abstract: FR-PO607
Poor Health-Related Quality of Life in Adult Patients With Lupus Nephritis
Session Information
- Glomerular Diseases: Lupus and Vasculitis
November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1302 Glomerular Diseases: Immunology and Inflammation
Authors
- Teng, Yoe Kie Onno, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
- Ma, Janice, Maple Health Group, New York, New York, United States
- Pisarczyk, Konrad, Maple Health Group, New York, New York, United States
- Leff, Richard, Kezar Life Sciences Inc, South San Francisco, California, United States
- Park, Eunmi, Kezar Life Sciences Inc, South San Francisco, California, United States
- Long, Li, Kezar Life Sciences Inc, South San Francisco, California, United States
Background
Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE) associated with considerable morbidity that has a devastating impact on a patient’s life. However, little is known about true impact of LN on a patient’s health-related quality of life (HRQoL) in an autoimmune disease that can affect several organ systems. The objective of this study was to summarize the evidence on the humanistic burden of LN in adult SLE patients.
Methods
A comprehensive targeted literature review was conducted in MEDLINE and Embase to identify studies in patients with adult and juvenile onset of LN, published in English between March 2012 and 2022. The search included conference abstracts indexed in Embase since 2019.
Results
Of 4,126 records identified in the medical databases, 9 reported on the HRQoL in adult patients with LN. The studies were conducted in the US (n=5), multiple countries worldwide (n=2), Latin America (n=1) and Europe (n=1). Active LN was significantly associated with poor scores in almost all domains of SF-36 suggesting a deterioration in multiple aspects of life, especially in physical and emotional functioning. The humanistic burden of active LN was more pronounced compared to SLE manifestations in other organ systems. Patients with active LN had significantly worse HRQoL measured by lupus-specific questionnaires such as LupusPRO and LupusQoL, compared to subjects with inactive LN or those with SLE only, with the most profound impact of active renal disease on procreation, fatigue, physical and emotional health. Three studies examined the perspectives of LN patients on facilitators and satisfaction of disease control and treatment. Physician- and patient-reported dissatisfaction were reported by 33% of nephrologists and 25% of patients and were associated with LN severity and various signs and symptoms of disease. The key patient-relevant aspects of LN treatment were hope for being normal/healthy, improved quality of life, and effective patient-physician communication regarding benefits and harms.
Conclusion
LN significantly affects HRQoL across multiple domains of life such as physical and emotional functioning that are particularly affected during periods of active disease. Despite various therapies available, 25% of patients are dissatisfied with their options, indicating a high residual unmet need.
Funding
- Commercial Support –